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Peritoneal dissemination is a frequent metastatic route for cancers of the ovary and 
gastrointestinal tract. Tumor cells metastasize by attaching to and invading through the 
mesothelial cell (MC) monolayer that lines the peritoneal cavity. Metastases are influenced by 
carcinoma-associated fibroblasts (CAFs), a cell population that derives from different sources. 
Hence, we investigated whether MCs, through mesothelial to mesenchymal transition (MMT), 
were a source of CAFs during peritoneal carcinomatosis and whether MMT affected the 
adhesion and invasion of tumor cells. Biopsies from patients with peritoneal dissemination 
revealed the presence of myofibroblasts expressing mesothelial markers in the proximity of 
carcinoma implants. Prominent new vessel formation was observed in the peritoneal areas 
harboring tumor cells when compared with tumor-free regions. The use of a mouse model of 
peritoneal dissemination confirmed the myofibroblast conversion of MCs and the increase in 
angiogenesis at places of tumor implants. Treatment of omentum MCs with conditioned media 
from carcinoma cell cultures resulted in phenotype changes reminiscent of MMT. Adhesion 
experiments demonstrated that MMT enhanced the binding of cancer cells to MCs in a 1-
integrin-dependent manner. Scanning electron microscopy imaging showed that the enhanced 
adhesion was mostly due to increased cell-cell interaction and not to a mere matrix exposure. 
Invasion assays suggested a reciprocal stimulation of the invasive capacity of tumor cells and 
MCs. Our results demonstrate that CAFs can derive from mesothelial cells during peritoneal 
metastasis. We suggest that MMT renders the peritoneum more receptive for tumor cell 
attachment/invasion and contributes to secondary tumor growth by promoting its 
vascularization. 
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Neoplasias originated adjacent to the peritoneal cavity, such as ovarian or 
colorectal cancers, frequently disseminate via transcoelomic route to develop peritoneal 
metastases, which evolve very rapidly and correlate with poor prognosis [1, 2]. Surgery 
is inefficient to render patients free of disease, resulting in low survival rates [3, 4]. In 
peritoneal metastasis, cancer cells detached from the primary tumor are transported by 
peritoneal fluid and spread locally to colonize the peritoneum [1, 2]. The organization of 
the peritoneum is simple; a single layer of mesothelial cells (MCs) lines a compact 
region that is composed of connective tissue with few fibroblasts, mast cells, 
macrophages, and vessels. MCs may acquire a myofibroblast-like phenotype, through 
an epithelial to mesenchymal transition (EMT)-like process, during inflammatory and 
repair responses (e.g. peritoneal damage induced by dialysis fluid) [5, 6]. MCs share 
characteristics with both epithelial and endothelial cells, which may undergo EMT and 
endothelial to mesenchymal transition (EndMT), respectively. Thus, recently we and 
other authors have proposed renaming the myofibroblast conversion of MCs, that takes 
place in different organs such as lung, liver or peritoneum, with a more appropriate 
term: mesothelial to mesenchymal transition (MMT) [7-11]. MMT is characterized by 
an increase in the invasive capacity of MCs, which allows them to invade the peritoneal 
compact zone. Mesenchymal MCs acquire the capacity to synthesize inflammatory and 
angiogenic factors, as well as extracellular matrix (ECM) components, thereby 
contributing to the deterioration of the peritoneum during chronic peritoneal injury [5, 
6].  
The first contact of metastasizing tumor cells with the peritoneum is provided by 
the MC monolayer. Inflammatory factors released by tumor and immune cells, as well 




as the formation of ascites, may alter the tissue architecture of the peritoneal membrane 
making it more receptive to further metastatic implantation [12, 13]. Inflammation 
promotes the mesenchymal conversion of MCs [6, 14], however, the possible role of the 
MMT process in the attachment of tumor cells to the peritoneum has been overlooked.  
Carcinoma-associated fibroblasts (CAFs) are a prominent cell type within the 
tumor stroma and participate in most stages of tumor progression [15]. CAFs share 
characteristics with myofibroblasts, including the expression of -smooth muscle actin 
(-SMA), and are considered activated fibroblasts capable of producing a wide array of 
growth factors, as well as ECM components, thereby contributing to the growth and 
vascularization of solid tumors [16]. There is emerging evidence that the origin of CAFs 
may vary between different cancers and within different areas of individual tumors [17]. 
The activation of resident fibroblasts has been considered the main origin of CAFs in 
the tumor microenvironment [18, 19]. More recent studies point to cells recruited from 
the bone marrow as a possible source of CAFs. In addition, it has been shown that 
endothelial cells, through an EndMT, may also be a source of CAFs [14, 17, 20]. 
Epithelial cells are considered an important source of activated fibroblasts during 
fibrosis [21], but it is unclear if normal epithelial cells convert into CAFs in tumors [18, 
22]. 
Herein, we show that CAFs located within or nearby peritoneal carcinoma 
implants expressed mesothelial markers. Cell culture experiments demonstrated that 
carcinoma cells secreted MMT-promoting factors and that the mesenchymal conversion 
of MCs favored cell-cell interaction with tumor cells. The results showed that 
mesenchymal MCs and tumor cells mutually stimulate their invasive capacity. We 
propose that the MMT of MCs plays an important role both in the initial steps of 




peritoneal metastasis and in the growth of secondary tumor implants. 




MATERIALS AND METHODS 
Analysis of biopsies from patients with peritoneal metastasis 
Peritoneal metastases from 5 serous ovarian carcinomas, 4 colonic 
adenocarcinomas, 3 pancreatic adenocarcinomas, 1 endometrial adenocarcinoma, and 
pleural metastases from 3 pulmonary adenocarcinomas were considered in this study. 
Informed written consent to use surgical samples was obtained from the patients, with 
the approval of the Ethics Committee of the Hospital de la Princesa (Madrid, Spain). 
Tissue samples were fixed in neutral-buffered 3.7% formalin and embedded in paraffin 
to obtain serial sections 3µm thick. Haematoxylin-eosin (H&E) and 
immunohistochemical (IHC) staining were performed as is described in Supplementary 
materials and methods. 
  
Mouse model of peritoneal carcinomatosis  
Swiss nu/nu 2-month-old mice were used in this study (Charles River 
Laboratories, Barcelona, Spain). The experimental protocol followed was in accordance 
with the National Institutes of Health Guide for Care and Use of Laboratory Animals 
and was approved by the Animal Ethics Committee of the “Unidad de Experimentación 
Animal” del Centro de Biología Molecular “Severo Ochoa” (Madrid, Spain). 
A total of 5x106 SKOV-3 cells were inoculated into the peritoneal cavity of 
mice. Mice were sacrificed at different time points (4 to 8 weeks) and then parietal and 
visceral peritoneal samples were collected for IHC and immunofluorescence analysis. 
Peritoneal specimens were routinely fixed in neutral-buffered 3.7% formalin and 
embedded in paraffin. Deparaffinized sections (3µm) were stained with H&E. IHC and 
immunofluorescence procedures are described in Supplementary materials and methods.  




Carcinoma cell lines, primary peritoneal MCs and induction of MMT 
The cell lines SKOV-3 and HT29, derived from human ovarian carcinoma and 
colorectal adenocarcinoma, respectively, were cultured in McCoy’s 5A medium 
supplemented with 10% fetal bovine serum (FBS). 
Human peritoneal MCs were obtained from omentum samples of patients 
undergoing elective surgery as previously described [5, 7, 8]. Procedures are detailed in 
Supplementary materials and methods. This study adjusts to the Declaration of Helsinki 
and it was approved by the Ethics Committee of Centro de Biología Molecular “Severo 
Ochoa” (Madrid, Spain). Informed written consent to use surgical samples was obtained 
from omentum donors. 
To induce MMT with conditioned media, omentum MCs were treated with 75% 
of carcinoma cell supernatants for 72 hours or 6 days as is described in Supplementary 
materials and methods. As a control of MMT in vitro, MCs were treated with 0.5 ng/mL 
of transforming growth factor-β1 (TGF-β1) plus 2.5 ng/mL of interleukin-1β (IL-1β) 
(R&D Systems) for 72 hours or 6 days, which has been proven to be a suitable MMT 
model [7, 8, 23]. To interfere with the MMT process, omentum MCs were treated for 72 
hours with SKOV-3 conditioned media or with TGF-β1 (1ng/mL) in the presence or 
absence of a selective inhibitor of the TGF-β Type I Receptor GW788388 (see 
Supplementary materials and methods). The analysis of MMT-related molecules was 
achieved by quantitative RT-PCR or western blot in mesothelial and SKOV-3 cells as 








Adhesion assays and scanning electron microscopy 
Adhesion assays of SKOV-3 cells labeled with Carboxyfluorescein diacetate 
Succinimidyl Ester (CFSE; Molecular Probes, Invitrogen) on MCs either treated or not 
with TGF-β1 plus IL-1β for 72 hours, were performed as is described in Supplementary 
materials and methods. 
For scanning electron microscopy analysis (see Supplementary materials and 
methods), a parallel experimental procedure was carried out in which coverslips were 
fixed in 3% glutaraldehyde. 
To characterize the adhesion molecules involved in tumor-mesothelium 
interaction, SKOV-3 cells labeled with the fluorescent probe BCECF-AM (Sigma-
Aldrich) were added to MCs, treated or not with TGF-β1 plus IL-β1, in presence of the 
monoclonal antibodies indicated in Supplementary materials and methods [24, 25]. 
 
Invasion assays 
Invasion assays were performed in 12-mm diameter transwell units (3.0 µm pore 
size; Corning, MA, USA). First, we analyzed the effect of MCs, with either epithelial-
like or mesenchymal-like phenotypes, embedded in the collagen matrix on SKOV-3 
cells invasion capacity. Next, we analyzed the effect of carcinoma SKOV-3 cells 
embedded in the matrix on MCs invasion capacity. The protocols for the invasion 
assays are detailed in Supplementary materials and methods. 
 
Statistical analysis 
Results are presented as 25th and 75th percentiles, median, minimum and 
maximum values in box plots graphics; and as mean ± SEM in bar graphics. The data 




groups were compared with the non-parametric Mann–Whitney rank sum U-test using 
the SPSS statistic package version 15.0 (Chicago, IL, USA) and GraphPad Prism 
version 5.0 (La Jolla, CA, USA). P<0.05 was considered statistically significant. 
 





Human biopsies analysis shows that CAFs originate from MCs and collaborate in 
tumor angiogenesis  
Histologic observation of peritoneal biopsies from human ovarian carcinoma 
implants showed the localization of metastatic foci in the submesothelial area 
surrounded by spindle-like cells.  Immuno-staining of serial sections showed overlapped 
expression of α-SMA and mesothelial markers, such as cytokeratins and calretinin, in 
the stromal tissue surrounding the tumor implants. As expected, cytokeratin staining 
also revealed the epithelial nature of metastasizing cells (Figure 1A). Additional 
mesothelial markers, like Wilm’s tumor protein-1 (WT1) and mesothelin, were also 
expressed in fibroblast-like cells proximal to peritoneal micrometastases derived from 
an endometrial adenocarcinoma (Figure 1B). The co-expression of mesothelial and 
mesenchymal markers suggested that in peritoneal metastases CAFs may derive from 
MCs via MMT. 
To confirm the mesothelial origin of CAFs, we took advantage of the differential 
expression of cytokeratins. Colon carcinoma cells express cytokeratin-20 but not 
cytokeratin-7 and, conversely, MCs express cytokeratin-7 but not cytokeratin-20. The 
analysis of peritoneal metastases of colon carcinoma in humans demonstrated that the 
expression of cytokeratin-20 was confined to tumor implants, whereas the expression of 
cytokeratin-7 was observed in the preserved mesothelium of tumor-free regions and in 
fibroblast-like cells located in the close proximity of tumor micrometastases (Figure 
1C). To further verify that CAFs may originate from MCs, we analyzed metastatic 
implants of lung cancers in the pleura, another anatomic cavity lined by mesothelium. 
We observed CAFs expressing calretinin close to cancer implants (Suppl. Figure S1). 




In addition, we did not observe expression of mesothelial makers in CAFs of tumors 
located outside the coelomic cavities (Suppl. Figure S2).  
It was shown that during the MMT process, MCs acquired the ability to produce 
large amounts of VEGF [26]. Thus, we hypothesized that CAFs derived from MCs 
could play a role in tumor vascularization. Quantification of the number of vessels in 
biopsies from peritoneal implants derived from different human cancers revealed a 
significant increase (p=0.002) in CD34-positive vessels in the areas of tumor 
micrometastasis compared with tumor-free zones from the same biopsies (Figures 2A 
to 2C). To confirm that CAFs derived from MCs participate in tumor angiogenesis, we 
took advantage of the fact that some tumors express low levels of VEGF. As shown in 
Figure 2D, an endometrial adenocarcinoma expressed low amounts of VEGF. In 
contrast, MC-derived CAFs (cytokeratin positive) appeared as high producers of VEGF 
(Figure 2E). 
 
CAFs originate from MCs in a mouse model of peritoneal dissemination   
Parietal peritoneal tissues stained with H&E showed a fibro-proliferative 
response at the sites of small tumor implants, with submesothelial accumulation of 
spindle-like cells and fibrosis, which were absent in tumor-free zones of the same 
samples (Figures 3A and 3B). IHC analysis showed intense cytokeratin staining of 
metastasizing cells and a weak cytokeratin staining in MCs located nearby, indicating 
that these MCs were undergoing a MMT process, which implied the down-regulation of 
cytokeratin expression. Surrounding the micrometastatic nodules there was a prominent 
accumulation of -SMA-positive fibroblasts. In the peritoneal region without metastatic 
implants there was no expression of α-SMA other than that in the smooth muscle cells 




of the vessel walls, and the expression of cytokeratin was limited to the preserved 
mesothelium (Figures 3C to 3F). To confirm the origin of CAFs, we used WT1 as an 
additional mesothelial marker. IHC analysis showed nuclear staining of WT1 in the 
preserved mesothelium of tumor-free regions and in submesothelial CAFs surrounding 
tumor implants (Figures 3G and 3H). Immunofluorescence techniques confirmed the 
presence of fibroblast-like cells that were double-positive for WT1 and α-SMA (Figure 
4). Western blot analysis demonstrated that SKOV-3 cells were negative for WT1 and 
α-SMA, and confirmed the down-regulation of cytokeratin and the induction of α-SMA 
during the MMT process (Suppl. Figure S3). 
Blood vessels of parietal tissues were stained with anti-CD31 antibody. There 
was a dramatic increase in the number of vessels in adjacent areas to micrometastases 
when compared with tumor-free regions (Figures 5A and 5B). The new vessels were 
mainly located in the upper submesothelial zone, where MC-derived CAFs expressing 
high levels of VEGF (Figures 5C and 5D) tended to accumulate, suggesting that MCs 
could, indeed, play an important role in tumor vascularization. 
Analysis of peritoneal specimens with larger implants showed that at advanced 
stages of peritoneal dissemination, the expression of cytokeratin was restricted to 
carcinoma cells. Nevertheless, WT1 and α-SMA-positive cells could be observed not 
only in the proximity of carcinoma implants, but also integrated within the tumor 
stroma (Suppl. Figure S4). 
Peritoneal metastases were also observed in the omental tissue, where 
cytokeratin and α-SMA-positive spindle cells were found in the interstitial stroma 
surrounding tumor implants (Suppl. Figure S5). 
 




Conditioned media from carcinoma cells induces MMT in vitro 
Incubation of omentum MCs with SKOV-3 cells conditioned media induced the 
acquisition of a spindle-like morphology that was evident at 72 hours and more 
pronounced at 6 days, with a similar appearance to that of MCs treated with TGF-β1 
plus IL-1β (Figure 6A). To verify the mesenchymal conversion of MCs, the expression 
patterns of MMT markers were analyzed by quantitative RT-PCR in cells treated with 
conditioned media for 72 hours. Under these conditions, the expression of E-cadherin 
was repressed and conversely, the expression of Snail was induced when compared with 
control media-treated cells (Figures 6B and 6C). The expression of other MMT 
markers (fibronectin, collagen I, VEGF and TGF-1) were up-regulated in MCs treated 
with conditioned media compared to control cells (Figures 6D to 6G). The molecular 
reprogramming after 6 days of treatment with SKOV-3 conditioned media was more 
profound (data not shown). 
Similar experiments were performed using the colorectal adenocarcinoma cell 
line HT29. Treatment of MCs with supernatant from HT29 cultures induced the 
acquisition of a spindle-like morphology, but this was evident only at 6 days (Suppl. 
Figure S6A). Repression of E-cadherin and the up-regulation of fibronectin and 
collagen-I also reached statistical significance at 6 days (Suppl. Figures S6B to S6D). 
 TGF-β1 is a key molecule in the mesenchymal conversion of MCs. Accordingly, 
experiments blocking the TGF-β type I receptor were performed. Quantitative RT-PCR 
analysis revealed that the selective inhibitor GW788388 blocked the induction of Snail, 
collagen I and fibronectin mediated by TGF-β1 or SKOV-3 conditioned media (Figure 
7).  
 




Mesenchymal conversion of MCs enhances the adhesion of tumor cells  
Adhesion experiments demonstrated that SKOV-3 cells had a significantly 
higher interaction capacity with mesenchymal-like MCs (stimulated with TGF-β1 plus 
IL-1β) than with untreated MCs (Figures 8A and 8B). We investigated whether -
integrins mediated the increased adhesion of tumor cells to MCs undergoing MMT. 
Treatment of cells with the blocking anti-β1 antibody Lia1/2 disrupted both the basal 
adhesion of SKOV-3 cells to untreated MCs and the increased adhesion to 
transdifferentiated MCs. Conversely, treatment with the activating anti-β1 antibody 
TS2/16 enhanced dramatically the adhesion of tumor cells to untreated MCs and to MCs 
treated with TGF-β1 plus IL-1β. Other blocking antibodies specific for the adhesion 
molecules VLA-1 (5E8D9) and β2-integrin (Lia3/2) did not affect the adhesion of tumor 
cells to MCs (Figure 8C). Our data demonstrated that the MMT promoted the adhesion 
of tumor cells and suggested that activated β1-integrin mediated, at least partially, the 
tumor cell-mesothelium interaction.   
To explore whether the enhanced adhesion of tumor cell to mesenchymal-like 
MCs was due to exposure of underlying matrix or to an increased cell-cell interaction, 
we carried out scanning electron microscopy imaging analysis. The images showed that 
SKOV-3 cells, maintaining a round-shaped morphology, laid on the monolayer of MCs 
with cobblestone features (Figure 8D). In contrast, SKOV-3 cells spread on 
transdifferentiated MCs loosing their round shape. Tumor cells emitted pseudopodial 
protrusions across the cytoplasmic extensions of mesenchymal-like MCs (Figure 8E). 
Detailed analysis of the images revealed that the enhanced adhesion of tumor cells was 
mostly due to increased cell-cell interaction and not to the underlying matrix exposed 
through the intercellular spaces.  




MCs and tumor cells mutually stimulate their invasive capacity 
We next investigated if mesenchymal MCs could promote the invasion of tumor 
cells.  SKOV-3 cells seeded on a collagen I matrix did not show invasive capacity. On 
the contrary, carcinoma cells seeded on matrix harboring MCs with an epithelial-like 
phenotype showed an increase in their invasive capacity. This effect was much more 
evident when MCs with a mesenchymal phenotype were embedded in the matrix 
(Figures 9A and 9B). The number of invading SKOV-3 cells increased significantly 
(p=0.003) when mesenchymal MCs were present in the matrix, compared with 
embedded epithelial-like MCs (Figure 9C).  
The histological analysis revealed that the MC monolayer was preserved in 
tumor-free regions but it was disrupted in areas with micrometastases, where CAFs 
expressing mesothelial markers could be observed (Figure 1C, Inset). These data 
suggested that tumor cells might, in turn, promote the invasion of the stroma by MCs. 
We performed in vitro invasion assays to analyze the effect of carcinoma cells on MC 
invasion capacity. SKOV-3 cells embedded in a collagen I matrix were able to attract 
the MCs from the monolayer into the matrix. In contrast, MCs seeded on collagen I 
matrix without cancer cells remained mainly as a monolayer (Figures 10A to 10C). The 
number of invading MCs showed a significant increase (p=0.03) when SKOV-3 cells 











The origin of CAFs has not been clearly established and it seems very likely that 
these activated fibroblasts are derived from various sources [16-18, 27, 28]. Herein we 
show, for the first time, that CAFs found in peritoneal metastatic implants derive from 
the mesothelium through a mechanism implicating tumor-induced MMT of MCs. The 
mesenchymal transition of MCs, in turn, favors the adhesion and invasion of 
metastasizing tumor cells and promotes the growth of secondary tumor implants 
(Summarized in Figure 11).  
The presence of MCs that have undergone MMT was first observed in the 
peritoneum of peritoneal dialysis patients [5, 29]. Afterwards, emerging evidence has 
suggested that MMT is an important event for peritoneal structural alteration, including 
fibrosis and angiogenesis [26, 30]. In this work, we show the presence of 
myofibroblasts expressing mesothelial markers, both in human biopsies and in mouse 
peritoneal specimens, suggesting that a subpopulation of CAFs stems from MCs during 
peritoneal tumor dissemination. In addition, we show a marked fibro-proliferative 
response and a prominent angiogenesis at the places of tumor implants, where MC-
derived CAFs accumulate. These results suggest that MMT plays important roles in 
tumor stroma formation and vascularization. The fact that MCs that have undergone 
MMT produce large amounts of VEGF [26] suggests that these cells may favor tumor 
angiogenesis and growth [31]. In this respect, it has been demonstrated that the 
expression of a soluble form of the VEGF receptor Flt-1 in the mesothelium suppresses 
the peritoneal metastasis of gastric tumors [32]. Experimental animal models of 
peritoneal fibrosis have demonstrated that treatments directed against MMT or against 
the MMT-promoting stimuli reduce the accumulation of myofibroblasts, ameliorate 




submesothelial fibrosis and angiogenesis and improve peritoneal function [6-8]. Thus, it 
is tempting to speculate that MMT may also be a putative therapeutic target to arrest 
peritoneal metastasis.     
Metastasizing cancer cells have two alternatives for attaching to the peritoneum: 
the surface of the MC monolayer or the exposed submesothelial matrix. It has been 
proposed that tumor cells prefer the ECM for first attachment. In this context, it has 
been shown that during the initial stages of peritoneal metastasis tumor cells bind 
predominantly to “milky spots” in which the ECM is exposed. Nevertheless, it is 
important to notice that secretions from tumor cells, as well as from MCs and immune 
cells, generate an inflammatory environment, which may influence peritoneal metastasis 
transforming the initial pattern of “milky spot” attachment into a widespread pattern of 
dissemination [33]. It has been hypothesized that tumor-associated inflammatory 
environment induces damage to the MC monolayer, leading to the exposure of the 
submesothelial connective tissue and providing a more favorable surface for tumor cell 
binding. Another important effect of inflammation is the triggering of myofibroblastic 
conversion of MCs [6, 34]; however, the involvement of the MMT process in the 
binding of tumor cells to the peritoneum had not been explored yet.  
The mesenchymal transition of MCs may play important roles in rendering the 
peritoneum more receptive for further metastatic implants. In this regard, our in vitro 
adhesion experiments demonstrate that tumor cells adhere better to mesenchymal than 
to epithelial-like MC monolayers. Scanning electron microscopy analysis reveals that 
the enhanced adhesion of tumor cells to mesenchymal MCs is not due to a mere 
exposure of underlying matrix but rather to an increased cell-cell interaction. The tumor 
cell-mesothelium interaction is mediated, at least in part, by β1-integrins [35, 36], which 




could reflect that cancer cells bind to mesothelium-associated ECM and/or to the MC 
adhesion molecule VCAM-1 [37]. In agreement with this notion, it has been described 
that cleavage of MC-associated matrix proteins fibronectin and vitronectin by MMP-2 
enhances integrin-mediated carcinoma-mesothelium attachment [38, 39]. Furthermore, 
it has been shown that blocking antibodies or siRNA directed against VCAM-1 or its 
ligand 41-integrin significantly decrease the adhesion and transmigration of SKOV-3 
cells through the MC monolayer [40]. Besides 1-integrins, other adhesion molecules, 
including CD44, CA125/MUC16 or ICAM-1, may also participate in the binding of 
cancer cells to mesothelium [41-46]. Determining the role of these molecules in tumor 
cell-mesothelium attachment along the mesenchymal conversion of MCs would require 
further analysis.   
Our histological analysis shows that numerous MC-derived CAFs accumulate in 
areas with micrometastases, but not in tumor-free regions, suggesting that tumor cells 
promote the invasion of adjacent MCs. Indeed, our in vitro invasion assays demonstrate 
that carcinoma cells embedded in the matrix enhance the invasive capacity of MCs. The 
enhanced invasion triggered by tumor cells could be a consequence of the acquisition of 
a mesenchymal phenotype by MCs. In fact, we have previously demonstrated that 
during the MMT process, MCs increase their migration/invasion capacity [23]. MCs 
that have invaded the matrix could, in turn, further promote the invasion of carcinoma 
cells. In this context, we demonstrate that MCs with mesenchymal phenotype embedded 
in the matrix markedly stimulate the invasion of SKOV-3 cells. Thus, these results 
suggest that mesenchymal MCs and carcinoma cells establish a feed-forward cycle by 
mutually stimulating their invasive capacity.  




Interestingly, MCs behave in a similar fashion to resident fibroblasts in terms of 
the induction of carcinoma cell invasion in vitro. It was shown that normal omentum-
derived fibroblasts induce the adhesion and invasion of carcinoma cells in 3D culture 
models [38, 47]. On the other hand, Cai et al, reported that activated fibroblasts (either 
CAFs isolated from malignant ovary carcinomas or normal omentum fibroblasts 
stimulated with tumor conditioned media) have much higher effects on carcinoma cell 
attachment and invasion than normal fibroblasts [19, 48]. We have also observed that 
MCs with a mesenchymal phenotype embedded in the matrix stimulate the invasion of 
SKOV-3 cells more than that of MCs with an epithelial-like phenotype.  
TGF-β1 is a key molecule controlling MMT and peritoneal fibrosis [8]. The 
measurement of TGF-β1 in the conditioned media from carcinoma cells showed that 
SKOV-3 cells produced higher levels of this cytokine than HT-29 (1141.6 ± 169.3 vs. 
369.4 ± 27.2 pg/mL). This might explain the stronger effect exerted by SKOV-3 cells 
on the mesenchymal conversion of MCs, when compared with HT29 cells. In addition, 
blockade of TGF-1 receptor prevented the mesenchymal conversion of MCs treated 
with conditioned media from SKOV-3 cells. TGF-β1 is a prototypical inducer of EMT 
and is also a key factor in the myofibroblastic differentiation of recruited fibrocytes and 
in the mesenchymal conversion of endothelial cells via EndMT [8, 27, 49, 50]. Thus, it 
can be speculated that accumulation of CAFs, regardless of their origin, could be 
interfered by targeting the TGF-1 pathway [51].  
The most important limitation of our study is that we have not performed 
lineage-tracing studies to formally demonstrate that the CAFs derived from MCs. The 
data do not exclude the possibility of de novo expression of mesothelial markers in 
activated fibroblasts. However, recent cell linage studies have demonstrated the myo-




fibroblast conversion of MCs during embryogenesis and in liver fibrogenesis, 
reinforcing our findings [10, 52].   
In conclusion, this work shows that myofibroblasts derived from MCs may 
adopt roles attributed classically to CAFs, forming a suitable metastatic niche to 
promote cancer adhesion/invasion and growth. Thereby, CAFs derived from adjacent 
mesothelium could constitute an alternative target in the treatment of metastases that 
disseminate via the peritoneum. 
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Figure 1: Analysis of human peritoneal carcinoma implants reveals the mesothelial 
origin for CAFs. A variable number of CAFs expressing calretinin were present in all 
the cases analyzed, not only in ovarian carcinomas metastases, but also in intestinal, 
pancreatic and endometrial ones. (A) H&E staining shows an ovarian cancer 
micrometastasis in the submesothelial area surrounded by spindle-like cells (panel a). 
IHC analysis of serial sections reveals overlapped expression of α-SMA and the 
mesothelial markers calretinin and cytokeratin in fibroblastic cells surrounding the 
tumor implant (panels b to d). Cytokeratins also stain the metastasizing cells, revealing 
their epithelial nature (panel d). Scale bars: 25μm. (B) Serial sections of a peritoneal 
implant of an endometrial cancer biopsy reveal the presence of fibroblastic cells 
expressing nuclear WT1 (panel a) and mesothelin (panel b). Mesothelin is also 
detected within the endometrial tumor mass. Scale bars: 100µm. (C) Biopsy of 
peritoneal metastasis from a patient diagnosed with colon carcinoma. Multiple tumor 
nodules express cytokeratin-20 while stromal cells close to metastatic implants are 
negative for this marker (panel a). In contrast, fibroblast-like cells surrounding tumor 
implants express the mesothelial marker cytokeratin-7. The inset shows a higher 
magnification of the delimited area (panel b). Scale bars: 100μm. T: Tumor. 
 
Figure 2: The number of vessels increases in areas adjacent to micrometastases, 
where MC-derived CAFs accumulate and express large amounts of VEGF. (A) 
Representative specimen of ovary cancer metastasis in peritoneum. The “Non-Tumor” 
image shows a submesothelial area from the biopsy without evidence of tumor implants 




and with a low number of vessels, which were mostly confined to the deeper compact 
zone. The “Tumor” image depicts a submesothelial area with micrometastases and 
elevated number of CD34-positive vessels. Scale bars: 100μm. (B) Separate analysis of 
three ovarian, two pancreatic, one colorectal and one endometrial-derived metastases 
consistently shows the differences. (C) Quantification of CD34-positive vessels 
observed in tumor implant areas compared to distant zones without evidence of 
peritoneal metastases. Box plot graphic depicts 25th and 75th percentiles, median, 
minimum and maximum values. Differences were statistically significant (p=0.002). 
(D) Representative case of endometrial adenocarcinoma metastasis in peritoneum. The 
tumor implant shows low expression levels of VEGF, which is mostly limited to 
endothelial cells in angiogenesis areas (panel a). Spindle-shaped CAFs surrounding the 
tumor mass express high levels of VEGF (panel b). Scale bars: 25µm. (E) Serial 
sections of the same case confirm that MC-derived CAFs (cytokeratin positive) 
proximal to the tumor produce large amounts of VEGF (panels a and b). Scale bars: 
25µm. T: Tumor. 
 
Figure 3: CAFs originate from MCs in a mouse model of peritoneal dissemination. 
Parietal peritoneum samples were analyzed by IHC four weeks after i.p. injection of 
SKOV-3 cells. (A and B) H&E staining shows that areas distant from tumor implants 
(Non-Tumor) have a conserved histological structure, without evidence of fibrosis and 
with a preserved MC monolayer. At the places of tumor implants there is a fibro-
proliferative response, with the accumulation of spindle-like cells. (C and D) IHC 
analysis shows cytokeratin expression in the preserved mesothelium of Non-Tumor 
regions. In the proximity of tumor implants, there is an intense cytokeratin staining in 




metastasizing tumor cells and a weak cytokeratin staining in MCs and in some 
fibroblast-like cells. (E and F) In the Non-Tumor areas there is no expression of α-
SMA other than that in the smooth muscle cells of the vessel walls. Surrounding the 
tumor implants there is accumulation of -SMA-positive fibroblasts. (G and H) WT1 is 
used as an additional MCs marker to confirm the mesothelial origin of CAFs.  IHC 
analysis reveals nuclear staining of WT1 in the preserved mesothelium of tumor-free 
regions and in submesothelial CAFs surrounding tumor implants. Arrows point to MC-
derived CAFs expressing cytokeratin, α-SMA or WT1 in the proximity of sub-
mesothelial tumor implants. The insets show higher magnifications of the delimited 
areas. Scale bars: 25μm. T: Tumor; Pan-CK: Pan-cytokeratin. 
 
Figure 4: Mesothelial-derived CAFs co-express WT1 and α-SMA in the mouse 
model of peritoneal dissemination. (A) Distant areas from tumor micro-implants show 
MCs forming a monolayer and expressing nuclear WT1 (green). MCs lining the 
peritoneum are exposed to factors produced by the tumor and, as a consequence, MCs 
with an apparently preserved structure begin to express low levels of α-SMA (red). (B) 
In areas close to the micrometastasis, MCs co-expressing WT1 (green) and α-SMA 
(red) change their original localization on the peritoneal surface and start to invade the 
sub-mesothelial compact zone. (C) CAFs co-expressing WT1 and α-SMA are 
embedded in the parenchyma of a micrometastasis cohabiting with tumor cells negative 
for both markers. Arrows point to MC-derived CAFs co-expressing WT1 and α-SMA. 
Scale bars: 10µm. 
 




Figure 5: Increased angiogenesis is found in sites where MC-derived CAFs 
expressing high amounts of VEGF accumulate. (A and B) CD31 staining reveals that 
non-tumor zones do not possess a high number of vessels. At the sites of tumor 
implants, there is a dramatic increase of vessels density, particularly located in the upper 
compact zone where MC-derived CAFs tend to accumulate. (C and D) VEGF is 
expressed in a preserved mesothelium distant from tumor implants. At tumor zones, 
MCs and MC-derived CAFs, as well as cancer cells, proximal to vascularized areas 
express high levels of VEGF. Arrows point to angiogenesis zones. Scale bars: 25μm. 
T: Tumor. 
 
Figure 6: Conditioned media from SKOV-3 cells induces MMT in vitro. (A) 
Treatment of omentum MCs with culture media from SKOV-3 cells induces the 
acquisition of a spindle-like phenotype that is evident at 72 hours and more pronounced 
at 6 days.  The morphology alteration of MCs is similar to that observed in cells treated 
with TGF-β1 plus IL-1β. Scale bars: 100μm. (B and C) The mesenchymal conversion 
of MCs treated with conditioned media is verified at the molecular level by qRT-PCR 
analysis of recognized MMT markers. The expression of E-cadherin is repressed in 
MCs treated for 72h with SKOV-3-derived conditioned media when compared with 
control media-treated MCs. On the contrary, the expression of Snail is up-regulated in 
MCs treated with conditioned media. (D to G) The expression of other MMT-associated 
markers including the matrix components fibronectin and collagen I, as well as the 
growth factors VEGF and TGF-β1, are also significantly up-regulated in MCs treated 
with conditioned media. Bar graphics represent mean ± SEM. Symbols represent the 




statistic differences between groups. F.I.: Fold Induction; SKOV-3 CM: SKOV-3 
Conditioned Medium; T+I: TGF-β1 plus IL-1β. 
 
Figure 7: TGF-β Type I Receptor blocking interferes with MMT induced by 
SKOV-3 conditioned media. Omentum-derived MCs were treated for 72 hours with 
TGF-β (1 ng/mL) or SKOV-3 conditioned media in the presence or absence of 2µM or 
5µM of GW788388. (A and B) Quantitative RT-PCR shows that GW788388 blocks the 
induction of fibronectin and collagen I mediated by TGF-β1 or SKOV-3 conditioned 
media. (C) GW788388 also blocks the up-regulation of the MMT-associated molecule 
Snail. Bar graphics represent mean ± SEM. Symbols represent the statistic differences 
between groups. F.I.: Fold Induction; SKOV-3 CM: SKOV-3 Conditioned Medium. 
 
Figure 8: Tumor cells adhere mainly to the transdifferentiated MC monolayer 
through cell-cell interactions. (A) Representative images show CFSE-labeled SKOV-3 
cells (green) adhered on omentum-derived MC monolayers (DAPI) that have been pre-
treated or not with TGF-β1 plus IL-1β. Scale bars: 100μm. (B) Tumor cells adhere more 
efficiently to mesenchymal-like MCs than to MCs with epithelial morphology. Results 
are presented as the number of adhered SKOV-3 cells per field. Box plot graphic 
depicts 25th and 75th percentiles, median, minimum and maximum values. Numbers 
above boxes depict mean ± SEM. Differences are statistically significant (p=0.04). (C) 
-integrins mediate the increased adhesion of tumor cells to transdifferentiated MCs. 
Treatment of MCs with the blocking anti-β1 antibody Lia1/2 reduces significantly both 
the basal adhesion of SKOV-3 cells to control MCs and the increased adhesion to 




transdifferentiated MCs. Conversely, treatments with the activating anti-β1 antibody 
TS2/16 markedly enhance the adhesion of tumor cells to control and transdifferentiated 
MCs. Other blocking antibodies specific for the adhesion molecules VLA-1 (5E8D9) 
and β2-integrin (Lia3/2) do not affect the adhesion of tumor cells to MCs. Results are 
depicted as percentage of adhered cells, considering the number of cells prior to wash as 
100%. Bar graphics represent mean ± SEM. Symbols represent the statistical 
differences between groups. T+I: TGF-β1 plus IL-1β. (D) High resolution images of co-
cultures were obtained by scanning electron microscopy techniques. The image analysis 
shows SKOV-3 cells laying on a monolayer of MCs with epithelial-like morphology. 
Tumor cells adhered to control monolayers maintain a round-shaped morphology. (E) 
Transdifferentiated MC monolayers show a disorganized structure on which numerous 
cancer cells spread out and lose their round aspect. At high magnification SKOV-3 cells 
display pseudopodial protrusions across the cytoplasmic extensions of mesenchymal-
like MCs. Detailed analysis of the images suggests that the enhanced adhesion of tumor 
cells to transdifferentiated MCs was mostly by means of direct cell-cell contacts. Scale 
bars: 10μm. T+I: TGF-β1 plus IL-1β. 
 
Figure 9: Mesenchymal-like MCs strongly stimulate the invasive capacity of 
carcinoma cells. (A and B) Transversal projection and 3D reconstructions of Confocal 
Laser Scanning Microscopy show that SKOV-3 cells (red) seeded on a collagen I matrix 
do not invade after five days. In contrast, carcinoma cells seeded on matrix harboring 
CFSE- and propidium iodide-labelled MCs (green + red) with either epithelial-like 
(MCs) or mesenchymal-like (MCs+T+I) phenotype show significant increase in the 
invasive capacity. This effect is much more evident when MCs with a mesenchymal 




phenotype are embedded in the matrix. Scale bars: 100μm. (C) Quantification analyses 
of SKOV-3 invading cells were performed subtracting CFSE-labelled MCs (green) 
from the total propidium iodide-stained cells (red) that invaded the matrix. Thus, the 
invasion of SKOV-3 corresponds to red cells in the merge panel, since embedded MCs 
are yellow (green + red). Results show the percentage of invading SKOV-3 cells in gels 
containing MCs versus gels containing MCs pre-treated with TGF-1 plus IL-1. Bar 
graphics represent mean ± SEM. The difference is statistically significant (p=0.003). 
T+I: TGF-β1 plus IL-1β. 
 
Figure 10: Tumor cells embedded in the matrix induce MC invasion. (A) H&E 
sections of paraffin embedded gels show the disruption of the MC monolayer when 
SKOV-3 cells are present in a collagen I matrix, mimicking a metastatic 
submesothelium. (B) Confocal images display transversal projections of CFSE- and 
propidium iodide-labelled SKOV-3 cells (green + red) embedded in a collagen I matrix. 
Carcinoma cells are able to attract MCs (red) from the monolayer into the matrix. 
However, MCs seeded on collagen I matrixes without cancer cells remain mainly as a 
monolayer. (C) Reconstructions in 3D of Confocal Laser Scanning Microscopy. (D) 
Quantification analyses of invading MCs were performed subtracting CFSE-labelled 
SKOV-3 cells (green) from the total propidium iodide-stained cells (red) that invaded 
the matrix. Thus, the invasion of MCs corresponds to red cells in the merge panel, since 
embedded SKOV-3 cells are yellow (green + red). Results show the percentage of 
invading MCs in gels containing SKOV-3 cells versus gels without tumor cells. Bar 




graphics represent mean ± SEM. The difference is statistically significant (p=0.03). 
Scale bars: 100μm. 
 
Figure 11: Tumor peritoneal dissemination model. (A) First contact and early 
MMT. Tumor cells dispersed in the peritoneal cavity initially attach to milky spots of 
mesothelium where they trigger an early MMT. The mechanisms behind cancer 
anchoring to the peritoneal barrier seem to involve the regulation of, at least, the β1-
integrin molecule by the mesothelium. (B) MMT progression. Mesothelial and 
cancer cell invasion. Cancer cell attachment is more apparent as the MMT advances. 
MCs acquire invasive capacity, providing cancer cells direct access to colonize the 
submesothelium. (C) Fibrosis, angiogenesis and CAF accumulation. The 
accumulation of submesothelial myofibroblasts via MMT (CAFs) provides the tumor of 
the adequate blood support and ECM components to survive. During disease 
progression, intraperitoneal tumor implants could nurture new CAFs recruited from the 











SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure S1: Analysis of human lung cancer-derived metastasis in 
the pleura. Two representative slides show calretinin-positive fibroblasts coexisting 
with large-cell lung carcinoma implants in pleura. These results support the mesothelial 
origin of CAFs. T: Tumor. Scale bars represent 100μm. 
 
Supplementary Figure S2: MC markers are not expressed in CAFs of tumors 
located outside the coelomic cavities. (A and B) Serial sections of a cutaneous basal 
cell carcinoma show CAFs negative for mesothelial markers (cytokeratin AE1/AE3 and 
calretinin) accompanying the tumor. (C) An infiltrating breast carcinoma positive for 
cytokeratin AE1/AE3 shows proximal CAFs negative for this mesothelial marker. Scale 
bars represent 25µm. T: Tumor. 
 
Supplementary Figure S3: Expression pattern of mesothelial markers in primary 
MCs, either treated or not with TGF-1 plus IL-1 and in SKOV-3 cells. Western 
blot analysis shows that SKOV-3 cells are negative for WT1, α-SMA and calretinin. 
The expression of pan-cytokeratin in SKOV-3 cells reveals its epithelial origin. On the 
contrary, omental-derived MCs express WT1, pan-cytokeratin and calretinin. The levels 
of these markers are dramatically down-regulated in MCs treated with TGF-β1 + IL-1β.  
The molecule α-SMA is increased in MCs transdifferentiated in vitro. Expression of β-
actin is employed as a loading control. 
 




Supplementary Figure S4: Large tumor implants coexist with fibrotic areas where 
CAFs express mesothelial markers. H&E analysis of advanced peritoneal 
disseminations (8 weeks after i.p. SKOV-3 cell injection) shows larger metastatic 
masses coexisting with widespread areas of fibrosis. IHC studies reveal the existence of 
CAFs expressing mesothelial markers not only in the proximity of carcinoma implants, 
but also integrated within the tumor stroma. The expression of cytokeratin is restricted 
exclusively to carcinoma cells. However, extended WT1 and α-SMA staining can be 
observed cohabiting with the large peritoneal tumors. The inset shows a higher 
magnification of the WT1 nuclear staining. Scale bars represent 100μm. T: Tumor. 
 
Supplementary Figure S5: Analysis of omental metastasis in the mouse model of 
peritoneal dissemination. (A) Visceral macroscopic metastases are observed in mice 
i.p. inoculated with SKOV-3 cells. (B) Immunohistochemical analyses of omental 
tissues reveal that MCs positive for cytokeratin are lining omentum in tumor-free areas. 
(C) Fibroblastic cells (CAFs) express pan-cytokeratin in the stroma interstices between 
cancer cells. (D) α-SMA is negative in MCs lining tumor-free omental tissue. (E) A 
higher magnification of the tumor mass shows spindle-like cells positive for α-SMA 
embedded in the tumor parenchyma. Scale bars represent 100µm (B and D) and 25µm 
(C and E). Arrows point to MCs expressing cytokeratin or α-SMA. T: Tumor. 
 
Supplementary Figure S6: Conditioned media from HT29 cells induces MMT in 
vitro. (A) Conditioned media obtained from the colorectal adenocarcinoma cell line 
HT29 was applied during 6 days to omentum-derived MCs to induce MMT. The 




treatment induced the acquisition of a spindle-like morphology in MCs. Scale bars 
represent 100μm. (B to D) MMT molecular reprogramming, including the repression of 
E-cadherin and the up-regulation of mesenchymal markers such as fibronectin and 
collagen-I, reach the statistical significance at 6 days of exposition to HT29 conditioned 
media. Bar graphics represent mean ± SEM. Symbols represent the statistic differences 
between groups. F.I.: Fold Induction; HT29 CM: HT29 Conditioned Medium; T+I: 
TGF-β1 plus IL-1β. 
 
